Pharmacokinetic Study of E7080/Lenvatinib in Chinese Patients With Unresectable Hepatocellular Carcinoma (HCC)
Status:
Completed
Trial end date:
2020-12-28
Target enrollment:
Participant gender:
Summary
The primary purpose of this study is to assess the single- and multiple-dose pharmacokinetic
(PK) profile of lenvatinib in Chinese participants with unresectable Hepatocellular Carcinoma
(HCC).